CGRP monoclonal antibodies: others

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

CGRP monoclonal antibodies: others. The dose for episodic migraine is 225mg monthly or 675mg quarterly SC. Fully referenced neurology checklist.

Fremanezumab

  • The dose for episodic migraine is 225mg monthly or 675mg quarterly SC
  • The quarterly dose for chronic migraine is 675mg SC
  • The monthly dose for chronic migraine is 675mg loading dose and 225mg monthly SC

Galcanezumab

Locked: subscribe to see this section.

Eptinezumab

Locked: subscribe to see this section.

Acronym

Locked: subscribe to see this section.

References

  1. Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015; 14:1081-1090. 
  2. Melo-Carrillo A, Noseda R, Nir R, Schain A, Stratton J, Strassman AM, Burstein R. Selective inhibition of trigeminovascular neurons by fremanezumab-a humanized monoclonal anti-CGRP antibody. J Neurosci 2017; pii: 0576-17 (Epub ahead of print).
  3. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. NEJM 2017; 377:2113-2122.
  4. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 2018; 319:1999-2008. 
  5. Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. Cephalalgia 2018; doi: 10.1177/0333102418772585 (Epub ahead of print).
  6. And 15 more. Subscribe to see the full list

Related checklists

Loading...